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CARDIOVASCULAR DISEASE PREVENTION
Prevention of cardiovascular
disease in asymptomatic people
Guy De Backer
Mortality due to cardiovascular disease (CVD) has
been declining rapidly in most Western European
countries since the 1970s or ’80s.1 This has resulted
in a signiﬁcant increase in life expectancy not only
at birth but also in adult and elderly people. The
increase in life expectancy during the last decades in
Europe is for the large majority related to the decline
in CVD mortality.2 Thus, one could ask the ques-
tion whether much more attention should be given
to CVD prevention. What is the rationale for
requesting continuous and even greater efforts in
CVD prevention?
RATIONALE FOR THE PREVENTION OF
CARDIOVASCULAR DISEASE
CVD is still the leading cause of premature death
and disability in industrialised countries, and is
taking the lead in developing countries. This results
in loss of productivity and in escalating costs of
healthcare. CVD due to atherothrombotic lesions is
largely preventable by adopting healthy lifestyles
and by controlling the major risk factors.
A comprehensive plan for prevention of CVD
should include:
< a population strategy for altering, in the whole
community, those lifestyle and environmental
factors and their socioeconomic determinants
that are the underlying causes of the mass
occurrence of CVD
< a high risk strategy for the identiﬁcation of high
risk people and action to reduce their risk factor
levels, and
< a plan for the prevention of recurrent events in
patients with established CVD. In this report
prevention of CVD in asymptomatic people is
discussed as part of the high risk strategy;
however, the population approach is of para-
mount importance and should always comple-
ment the other.
Given the limited resources that are available for
prevention in most health care systems, priorities
have to be set and the resources that are available
should be used as efﬁciently as possible, which
means that one should adapt the intensity of
interventions in accordance with the total risk to
the population. In the guidelines that were issued
by the 4th Joint Task Force of European Societies on
prevention of CVD in clinical practice3 the
following priorities were set:
< Patients with established CVD should receive
maximum attention; they are all at high or very
high risk for recurrent events, and estimation of
total cardiovascular (CV) risk using speciﬁc
models is not necessary and not applicable to
these patients.
< The second priority relates to asymptomatic
subjects at high risk for developing CVD. These
are, on the one hand, subjects with type 2
diabetes or with notably elevated risk factors,
particularly in the presence of target organ
damage; they represent a rather small fraction
of the middle aged and elderly population, and
because of their condition (known diabetes,
severe arterial hypertension, severe hypercholes-
terolaemia) the chances that they are detected by
health professionals are great. On the other hand
there exists a larger proportion of middle aged and
elderly people at risk for developing CVD because
of a clustering of multiple risk factors, resulting in
an elevated total CV risk. This is the group that is
addressed in this article; they make up a large
fraction of middle aged subjects from which
a great number of new CVevents will arise.
Based on population surveys one can assume that
around 10e15% of the population is at high risk
because of established CVD or diabetes, only a small
fraction (estimated at 5e10%) is at low risk, while
between 75e80% of the asymptomatic middle aged
and elderly people are at mild, moderate, high or
very high total CV risk.
WHY ESTIMATE THE TOTAL CV RISK IN
ASYMPTOMATIC PEOPLE, AND HOW?
Many clinicians are still looking after single CV risk
factors in lipid clinics, in departments of diabetology,
in hypertension clinics, etc. Within this single risk
factor approachmost practitioners thinkof risk factors
in a dichotomous way; patients are divided into
hypertensive versus normotensive, diabetic versus
non-diabetic, hypercholesterolaemic versus normo-
cholesterolaemic. This has the disadvantage that
those who do not qualify for the deﬁnition of hyper-
tension, diabetes or hypercholesterolaemia receive no
attention at all because they are considered as ‘normal’.
Results from cohort studies have clearly shown
the continuous character of the association
between the cardinal risk factors and the risk of
developing CVD. There is no ‘normal’ blood pres-
sure or a ‘normal’ total cholesterol value. The higher
the blood pressure level or the cholesterol concen-
tration, the higher the relative and absolute risk for
developing CVD; the reverse is also true; results
from intervention studies show that the more the
blood pressure or cholesterol can be reduced the
lower the risk for developing CVD can be brought.
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However, this implies that for the prevention of
CVD, many people have to take precautions in
order to avoid clinical events occurring in only
a few. This brings us back to what Rose expressed
as the prevention paradox: ‘a preventive measure
that brings large beneﬁts to the community offers
little to each participating individual.’4
When the preventive measure is completely
harmless and well accepted by the community then
the measure should be taken. However, when
people are poorly motivated, the preventive
measure is difﬁcult to implement. Sometimes even
asymptomatic people are more likely to take daily
drugs to prevent CVD, although the long term
compliance with such actions is also poor. Most
people are generally motivated for drug treatment
by the prospect of an immediate and tangible
beneﬁt. The only return for asymptomatic people
who take action to prevent CVD is that nothing
happens.
Furthermore, starting lifelong drug treatment in
a large proportion of the population can be ques-
tioned in terms of labelling healthy people as ‘at
risk’ for decades.
The search for more efﬁcient preventive strate-
gies leads to the high risk strategy in which efforts
are focused on those people who are assessed as
being most likely to develop CVD.
The understanding of the importance of clus-
tering of risk factors is also difﬁcult because most of
these risk factors interact in a complex way to build
up the total CV risk. These interactions are difﬁcult
to grasp without using appropriate models that are
based on observations from prospective studies.
Preventive actions should be guided in accordance
with that total CV risk level.
Those at highest total risk should be identiﬁed
and targeted for intensive lifestyle interventions
and, when appropriate, for drug treatments;
however, the rest of the population should not be
left alone. The aim of introducing total CV risk in
the high risk strategy by the Joint European task
forces is to help the clinician in making decisions on
how intense his or her action should be, ranging
from a simple reinforcement of a health education
message to combinations of intensive professional
lifestyle change programmes in addition to drug
treatments for elevated blood pressure, dyslipi-
daemia or dysglycaemia.
In many instances, however, clinicians use the
total CV risk models in a dichotomous way: high
risk, deﬁned by whatever criteria, is a reason to do
everything, particularly drug prescription; below
that level, nothing is done. This may be partly due
to the fact that in most guidelines an arbitrary cut
point is used to deﬁne those at highest risk.
However, there is no consistency in deﬁning that
arbitrary level. This is illustrated in table 1 where
deﬁnitions of high total CV risk are given from
different sources:
< The 2nd Joint European Societies’ Task Force5
estimated the risk for developing any coronary
heart disease (CHD) event including angina,
based on a model from the Framingham study
by Anderson6; a total coronary risk of devel-
oping CHD of $20%/10 years was labelled as
high.
< In the National Cholesterol Education Program
Adult Treatment Panel III (NCEP-ATPIII) guide-
lines7 a model is proposed to estimate CHD risk
based on another Framingham model that
predicts only hard coronary events; a similar
cut point of $20% was used to deﬁne elevated
total CHD risk.
< The second Joint British Societies guidelines8 use
still another Framingham model with an esti-
mate of CVD instead of CHD as outcome, and
also deﬁne high risk as a level of $20%.
< The Third Joint European Societies’ Task Force9
recommend the use of the SCORE model in
Europe, either the charts for low risk countries,
high risk countries or calibrated charts with$5%
chances of dying in the coming 10 years from
CVD as high risk criterion.
< In the guidelines of the World Health Organiza-
tion/International Society of Hypertension
(WHO/ISH10) and the European Society of
Hypertension/European Society of Cardiology
(ESH/ESC11) on the management of arterial
hypertension, blood pressure and an aggregate
of risk factors is recommended to estimate total
CV risk and to deﬁne high risk.
It should be emphasised that all these cut points
are arbitrary and based on practical considerations
in relation to the health care system, health insur-
ance plans and economic determinants, but not on
strong scientiﬁc bases. The choice of the cut point
to deﬁne highest risk is primarily based on the need
to reﬂect the ability of the health system and of the
insurance plan to care for these high risk persons.
When evidence is lacking, thresholds are often
determined by balanced workload against projected
costs. This has led to a simple division of the
asymptomatic population into two groups: the
high risk, and all the others. This again may lead to
an inappropriate approach where the resources are
only used in the smaller fraction of the population
at highest risk, while in the large number of people
at mild or moderate risk no preventive actions are
taken.
The importance of this is also illustrated by
recent studies where the focus has been on lifetime
risk of developing CVD.12
Table 1 Definitions of high risk in asymptomatic people based on total cardiovascular
risk estimations
Guideline Criteria for high risk category
2nd Joint European Task Force2 Framingham$20% total CHD risk/10 years
NCEP-ATPlll7 Framingham $20% hard CHD risk/10 years
JBS28 Framingham $20% CVD/10 years
3rd Joint European Task Force9 SCORE $5% fatal CVD risk/10 years (low
and high risk countries, calibrated charts)
ESH/ESC11 BP + aggregate of risk factors, MS,
diabetes, established CV or renal disease
WHO/ISH10 BP + aggregate of risk factors, TOD and
associated clinical conditions
BP, blood pressure; CHD, coronary heart disease; CVD, cardiovascular disease; ESC, European Society of
Cardiology; ESH, European Society of Hypertension; ISH, International Society of Hypertension; JBS, Joint British
Societies; MS, metabolic syndrome; TOD, target organ damage; WHO, World Health Organization.
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In the Framingham study, results from long term
follow-up of the cohorts demonstrate that the
absence of established risk factors at the age of
50 years is associated with a very low lifetime risk
for CVD and notably longer survival. However, as
soon as one risk factor is present, risk increases
substantially in both men and women (table 2).
Participants with an optimal risk factor proﬁle had
substantially lower lifetime risk of CVD: 5.2% vs
68.9% in men with $2 major risk factors; 8.2%
lifetime risk in women with an optimal risk factor
proﬁle versus 50.2% in women with $2 major risk
factors. Survival was also very different: for those
men and women with an optimal risk factor proﬁle,
survival was >11 years and >8 years longer,
respectively, compared with those with $2 major
risk factors.
For both men and women the adjusted cumula-
tive incidence curves across aggregate risk strata
separated early and continue to diverge through the
remaining lifespan.
It should also be said that only 3.2% of all men
and 4.5% of all women in that cohort had an
optimal risk factor proﬁle, deﬁned as total choles-
terol <4.65 mmol/l, blood pressure<120/<80 mm
Hg, non-smoker, and non-diabetic.
In a screening of a large working population of
>20 000 men and 5000 women aged 35e59 years in
Belgium, anoptimal risk factor proﬁlewasdeﬁned as:
<130/80 mm Hg for blood pressure, <190 mg/dl
(<5 mmol/l) for total cholesterol, non- or ex-
smoker, and a body mass index (BMI) <25 kg/m2.
Only 2.2% of all the men and 6.9% of the women
corresponded to these criteria (unpublished results
from the Belstress I study).
Another illustration of the limitation of using
arbitrary cut points in deﬁning high CV risk is given
by using the concept of the metabolic syndrome.
The NCEP-ATP III group deﬁnes the metabolic
syndrome when three out of ﬁve risk factors are
present based on a categorical deﬁnition of elevated
risk:
< abdominal obesity: men>102 cm,women>88 cm
< triglycerides $150 mg/dl ($1.7 mmol/l)
< high density lipoprotein (HDL) cholesterol: men
<40 mg/dl (1 mmol/l), women <50 mg/dl
(1.3 mmol/l)
< blood pressure$130/85 mm Hg
< fasting glucose $110 mg/dl ($6 mmol/l)
The prevalence of the metabolic syndrome,
according to this deﬁnition, was studied in a sample
of the population of a rural town in Belgium
including 2524 subjects aged 35e55 years, all free of
CVD. CV risk factors were measured by stand-
ardised methods, and the intimaemedia thickness
(IMT) in both carotid and femoral arteries was
assessed by a single trained observer. An increased
IMT was deﬁned as a thickness $0.9 mm in the
common carotid arteries or in the femoral arteries.
In ﬁgure 1 the relationship is shown between the
number of the different components of the meta-
bolic syndrome and the presence of an increased
IMT. The relationship is very clear, but not in the
sense that all those with the metabolic syndrome
have an increased IMT and all the others do not;
there is a clear gradientdthe more components
present, the higher the prevalence of increased IMT.
Furthermore, the prevalence of the metabolic
syndrome was 9% in this population, but 50% of
the population had at least one component; this
means that the proportion of increased IMT
attributable to the metabolic syndrome was 28%,
but 46% could be attributed to the presence of one
or two components (ﬁgure 2).
From all this one has to conclude that prevention
measures need to begin decades before the age of
50 years, because even the presence of a single major
risk factor at that age is associated with substan-
tially increased lifetime risk for CVD and notably
shorter survival. Lifestyle measures focusing on diet
and exercise in young adulthood and middle age
could prevent the development of obesity, diabetes,
hypertension and dyslipidaemia in large numbers of
individuals.
However, too much emphasis has been given to
an arbitrary cut point of high risk, deﬁned as a total
risk of dying from CVD of $5% within the coming
10 years by the SCORE model, or a total risk of
developing CHD of $20% by the Framingham
model. Some practitioners have reduced these
recommendations to the simple approach that drug
treatment for elevated blood pressure or total
cholesterol should be prescribed if total CV risk
exceeds that arbitrary cut point. Consequently, very
little is done in that large proportion of the
asymptomatic population who are at lower risk but
certainly not at optimal levels.
Focusing solely on short term risk results in
treatment only for older individuals with substan-
tial risk factor burden. Younger and middle aged
individuals at a modest risk factor level may have
low short term risk but substantial lifetime risk.
Therefore, not only should those individuals at
highest risk be identiﬁed and managed, but also
those at high risk should receive professional advice
regarding lifestyle changes and, in certain cases,
drug treatment to control their risk factors. More-
over, those at modest risk should not be ignored; in
these subjects, measures should be taken to prevent
the further development of their total risk, increase
awareness of the danger of CV risk, improve risk
communication, and promote efforts of primary
prevention. In those at low risk, all actions
necessary to keep their risk as low as possible
should be taken.
Table 2 Lifetime risk for cardiovascular disease (CVD) by risk factor burden at 50 years
of age
Risk factor burden*
Adjusted cumulative CVD incidence (%)
Men Women
All optimal 6 8
$1 not optimal 36 27
$1 elevated 46 39
One major risk factor 50 39
$2 major risk factors 69 50
Adapted from Lloyd-Jones et al.12
*For definitions see the original article.
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MANAGEMENT OF RISK FACTORS IN
ASYMPTOMATIC PEOPLE AT HIGH CV RISK
After assessing the total CV risk level, the next
important step inmanagement is setting appropriate
goals. These goals are given in different guidelines
such as the WHO/ISH guidelines on hyperten-
sion10 with emphasis on developing countries, in
those from the NCEP-ATPIII7 developed in the USA,
or the most recently developed guidelines in Europe
from the ESH/ESC on hypertension11 and from the
4th Joint European Societies’ Task Force on
prevention of CVD in clinical practice.3
Thresholds and goals can be used for different
purposes. In the guidelines they are mainly used as
management tools to help the clinician and the
patient to reach the most optimal situation
regarding the prevention of a ﬁrst or recurrent
event.
Goals can also be used as tools for auditing the
care of high risk subjects and of patients in general
practice or in hospitals.
In the guidelines of the 4th Joint European
Societies’ Task Force, there are two sets of goals:
< a number of objectives that one should try to
reach in the community at large
< a number of more stringent goals set for patients
with established CVD or at high absolute risk.
At the level of the community one should try to
keep the small minority that is at low risk in that
optimal state, while the larger group at mild or
moderate risk should be helped to reduce their risk
as low as possible with lifestyle changes in the ﬁrst
place. The goals are:
< smoking cessation
< making healthy food choices
< being physically active, which means at least 30
min of moderate activities per day
< maintaining BMI <25 kg/m2 and avoiding
central obesity
< maintaining blood pressure <140/90 mm Hg,
total cholesterol <5 mmol/l, and low density
lipoprotein (LDL) cholesterol <3 mmol/l
< having a fasting glycaemia <6 mmol/l.
In asymptomatic subjects at high CV risk, esti-
mated with the most appropriate model, a more
rigorous risk factor control should be achieved and
therefore the goals set in these subjects are more
stringent:
< when it comes to lifestyle changes the goals may
be similar, but dieticians, exercise physiologists
and smoking cessation advisors should be taken
on board whenever needed
< regarding the classical risk factors, the goals are
now at lower values:
– blood pressure <130/80 mm Hg if feasible
– total cholesterol <4.5 mmol/l with an option
of <4 mmol/l if feasible
– LDL cholesterol <2.5 mmol/l with an option
of <2 mmol/l if feasible
– fasting blood glucose<6 mmol/l and HbA1c at
<6.5% if feasible.
With the wording ‘if feasible’ the guidelines refer
both to clinical and economic conditions. For
example, establishing a cholesterol goal for treatment
ismostly an extrapolation from the apparent beneﬁts
indicated bymajor trials of lipid lowering; these trials
have a limited external validity; in particular cases of
complex dyslipidaemia goals need to be adapted; and
health economic conditions may also prevent the use
of certain very expensive drug regimens.
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Figure 1 Relationship between the number of the different components of the metabolic syndrome (MS) and the
prevalence of an increased intimaemedia thickness (IMT). Unpublished results from the Asklepios study.
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Applied to the lipid management of high risk
individuals, this means that the ﬁrst step is to
assess total CV risk and to identify those compo-
nents of risk that are to be modiﬁed. If the 10 year
risk of CV death according to the SCORE
modeldincluding also the qualifying risk factors
that can be considered outside those in the
chartsdis <5%, professional advice on diet, regular
activity and smoking cessation should be given to
keep the CV risk low. Risk assessment should be
repeated at 5 year intervals.
Note that the estimation of total CV risk does
not pertain to patients with familial hyper-
cholesterolaemia, since this condition by itself
places these patients at high total CV risk.
If the 10 year risk of CV death is $5% a full
analysis of plasma lipoproteins should be performed
and intensive lifestyle advice should be given. If
values of total and LDL cholesterol fall below 5 and
3 mmol/l, respectively, and the total CV risk esti-
mate has become <5%, then these individuals
should be followed at yearly intervals. In contrast, if
total CV risk remains $5%, lipid lowering drugs
should be considered to lower total and LDL
cholesterol even further to the goals that have been
set. These guidelines on lipid management are in
accordance with those that have been given by the
US NCEP-ATP III panel.7
Regarding the management of elevated blood
pressure, a stepwise approach is recommended.
First, it should be emphasised that ‘management’
means a variety of lifestyle advice for all those with
raised blood pressure, including dietary changes and
appropriate recommendations regarding physical
activity, in addition to the judicious use of medica-
tion in some individuals.
The decision to start antihypertensive drug
treatment depends on the presence or absence of
established CVD, diabetes, renal disease, target
organ damage and, of critical importance in all
other persons, on the estimate of total CV risk.
Those individuals in whom repeated blood pres-
sure measurements show grade 2 or 3 hypertension
are generally regarded as candidates for antihyper-
tensive treatment; this is because a large number of
placebo controlled trials have conclusively demon-
strated that in patients with these blood pressure
measurements, reduction lowers CV morbidity and
mortality.
The likely beneﬁts of drug treatment should be
weighed against side effects, costs, the use of
medical resources, and turning healthy people into
‘patients’.
In all grade 1e3 hypertensives, comprehensive
risk factor assessment and appropriate lifestyle
counselling should be provided after hypertension is
diagnosed, while promptness in the initiation of
drug treatment depends on the level of the total CV
risk. Drug treatment should be initiated promptly
in grade 3 hypertension as well as in grade 1 and 2
hypertensives with increased or notably increased
total CV riskdfor example, in hypertensives with
established CVD or renal disease, target organ
damage, diabetes or a SCORE risk $5%.
In grade 1 or 2 hypertensives with moderate total
CV risk, drug treatment may be delayed for some
time to allow evaluation of the effects of lifestyle
interventions on total CV risk. However, even in
these individuals, lack of blood pressure control
after a suitable period of non-pharmacological
intervention should lead to the initiation of drug
treatment in addition to lifestyle measures.
erom ro 43210
)III PTA( stnenopmoc SM fo rebmuN
%01
%02
%03
%04
e
P
r
c
e
n
t
a
g
e
 
o
f
 
s
u
b
j
e
c
t
s
 
(
%
)
%04
%43
%71
%7 %2
stcejbus fo %05 >
 evah SMtuohtiw
 SM 1 tsaelta
! tnenopmoc
: TMIdesaercnI
:SM otelbatubirttA *
28%
2-1 otelbatubirttA *
:SM fo stnenopmoc
46%
stluserdehsilbupnu :ydutSsoipelksA ehT
Figure 2 Distribution of the number of components of the metabolic syndrome (MS) in the Asklepios population.
Unpublished results from the Asklepios study. IMT, intimaemedia thickness.
Heart 2010;96:477e482. doi:10.1136/hrt.2009.169045 481
Education in Heart
 group.bmj.com on January 20, 2011 - Published by heart.bmj.comDownloaded from 
When initial blood pressure is within high-
normal range (130e139 mm Hg systolic) the deci-
sion on drug intervention depends heavily on total
CV risk. In case of diabetes or a history of CVD,
evidence justiﬁes the recommendation to start
antihypertensive drug treatment.
Lifestyle changes are very important in all
patients:
< to reduce the blood pressure
< to reduce CV risk in general
< to help in limiting the number and doses of
drugs.
Lifestyle changes are also important in subjects
with high-normal blood pressure levels in order to
prevent or delay the development of overt hyper-
tension. Recommendations should not be given as
lip service, but instituted with adequate behav-
ioural and expert support and periodic reinforce-
ment. Lifestyle changes relate to smoking, physical
activity and diet, in particular salt intake, alcohol,
fat, and fruits and vegetables.
The primary goal of good management of arterial
hypertension is to achieve maximal reduction in
the long term risk of CVD. This requires treatment
of the raised blood pressure as well as all other
reversible risk factors.
In conclusion, applying guidelines is a balancing
act of patient individualised care, improved patient
adherence to lifestyle changes and medication
regimens, and working within healthcare systems
intent on controlling costs. The objectives are to
help health professionals to reduce the occurrence
of CVD and their complications, and to encourage
the development of recommendations through the
formation of multidisciplinary national guidance
and implementation partnerships that are
compatible with local political, social, economic
and medical circumstances.
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